RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorption; 280 nm is not useful. |
| Confirmatory method | Electrospray mass spectrometry | Verifies mass near 3108 Da. |
| Solution stability | Limited at room temperature | Aqueous solutions degrade faster than powder. |
| Recommended storage | -20 °C | For lyophilized powder; protect from moisture. |
| Purity criterion | ≥95% by RP-HPLC | Typical research-grade specification. |
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Genetic testing is the most definitive test. If genetic testing is not available, a muscle biopsy with protein immunoanalysis can be used. Biopsy shows general dystrophic features, such as areas of muscle death, variability in muscle size, nuclei in the center of muscle fibers, and disorganized muscle fibers within muscle cells. Serum creatine kinase, a nonspecific marker of muscle damage, can be elevated early in the disease. Facioscapulohumeral muscular dystrophy (FSHD) can present similarly, although facial weakness and asymmetrical weakness is common in FSHD.
All the proteolytic activity of the asparagine peptide lyases is only self-cleavages, then no further peptidase activity occurs. The main residue of the active site is the asparagine and there are other residues involved in the catalytic mechanism, which are different between the different families of asparagine peptide lyases. The cleavage mechanism consists in the cyclization of the asparagine, assisted by other active site residues. In certain conditions, the asparagine cyclic structure nucleophilically attacks its C-terminal peptide bond to the main chain forming a new bond to create a stable succinimide, cleaving itself from the main chain and consequently releasing the two halves of the product. No inhibitors are known.
=== Trim weights in aircraft === Aircraft that contain depleted uranium trim weights for stabilizing wings and control surfaces (such as the Boeing 747–100) may contain between 652 and 1,059 pounds (296 and 480 kg) of DU. This application is controversial because the DU might enter the environment if the aircraft crashes. The metal can also oxidize to a fine powder in a fire. Its use has been phased out in many newer aircraft. Boeing and McDonnell-Douglas discontinued using DU counterweights in the 1980s. Depleted uranium was released during the crash of El Al Flight 1862 on 4 October 1992, in which 152 kilograms (335 lb) was lost, but a case study concluded that there was no evidence to link depleted uranium from the plane to any health problems. DU counterweights manufactured with cadmium plating are considered non-hazardous as long as the plating is intact.
Sources: en.wikipedia.org
Inspections and audits like also be conducted on a regular basis to assess hazards due to chemical handling and storage, electrical equipment, biohazards, hazardous waste management, chemical waste, housekeeping and emergency preparedness, radiation safety, ventilation as well as respiratory testing and indoor air quality. An important element of such audits is the review of regulatory compliance and the training of individuals who have access to or work in the laboratory. Training is critical to the ongoing safe operation of the laboratory facility. Educators, staff and management must be engaged in working to reduce the likelihood of accidents, injuries and potential litigation. Efforts are often made to ensure laboratory safety videos are both relevant and engaging.
== Veterinary use == Sufentanil is used both as an analgesic and as part of an anaesthetic protocol. In cats the half-life of sufentanil is longer than that of fentanyl and alfentanil. In dogs sufentanil produces a better anaesthetic recovery with similar analgesic and respiratory depression than fentanyl. One report suggest that for post-operative pain bupivacaine and sufentanil provides greater analgesia than fentanyl and bupivacaine in dogs. There is little information on the use of sufentanil in large animals. Due to the greater risk of cardiovascular and respiratory depression sufentanil is rarely used in practice.
=== Distribution === The apparent oral volume of distribution (VSS/F) at steady state of (R)-bicalutamide with oral administration of a single 5 to 80 mg dose of (R)-bicalutamide in a novel solid dispersion with a polymeric matrix of hydroxypropyl methylcellulose phthalate (HP55S) (also known as (R)-bicalutamide/HP55S) ranges from 22.53 ± 3.71 L to 25.38 ± 2.69 L. Bicalutamide is highly protein-bound (96.1% for racemic bicalutamide, 99.6% for (R)-bicalutamide), mainly to albumin. It has negligible affinity for SHBG and no affinity for corticosteroid-binding globulin. The tissue distribution of bicalutamide is not well-characterized. However, it has been reported that distribution studies with bicalutamide have shown that preferential (i.e., tissue-selective) accumulation in anabolic (e.g., muscle) tissues does not occur. There are no available data on hepatic bicalutamide concentrations in humans, but a rat study found that oral bicalutamide treatment resulted in 4-fold higher concentrations of the drug in the liver relative to plasma (a common finding with orally administered drugs, due to transfer through the hepatic portal system prior to reaching circulation). In men receiving 150 mg/day bicalutamide, concentrations of (R)-bicalutamide in semen were 4.9 μg/mL (11 μmol/L), and the amount of the drug that could potentially be delivered to a female partner during sexual intercourse is regarded as low (estimated at 0.3 μg/kg) and below the amount that is required to induce changes in the offspring of laboratory animals.
The FDA alerted medical practitioners that it had received nine additional reports of the same type and requested all health care professionals to report any such cases to the agency’s MedWatch program, or to their respective pharmaceutical manufacturers. The FDA subsequently received over a hundred additional reports of valvular heart disease in people taking fen-phen, fenfluramine alone, or dexfenfluramine alone. The FDA requested that the manufacturers of fenfluramine and dexfenfluramine stress the potential risk to the heart in the drugs' labeling and in package inserts. The FDA continued to receive reports in 1997 of valvular heart disease in people who had taken these drugs. This disease typically involves the aortic and mitral valves. After reports of valvular heart disease and pulmonary hypertension, primarily in women who had been undergoing treatment with fen-phen or (dex)fenfluramine, the FDA requested its withdrawal from the market in September 1997. The action was based on findings from doctors who had evaluated people taking these two drugs with echocardiograms, a procedure that can test the functioning of heart valves. The findings indicated that approximately 30 percent of people who had taken the combination for up to 24 months had abnormal echocardiograms, even though they had no symptoms. This percentage of abnormal test results was much higher than would be expected from a sample of the population who had not been exposed to either fenfluramine or dexfenfluramine.
Sources: en.wikipedia.org
== Dihydrogen bond == The hydrogen bond can be compared with the closely related dihydrogen bond, which is also an intermolecular bonding interaction involving hydrogen atoms. These structures have been known for some time, and well characterized by crystallography; however, an understanding of their relationship to the conventional hydrogen bond, ionic bond, and covalent bond remains unclear. Generally, the hydrogen bond is characterized by a proton acceptor that is a lone pair of electrons in nonmetallic atoms (most notably in the nitrogen, and chalcogen groups). In some cases, these proton acceptors may be pi-bonds or metal complexes. In the dihydrogen bond, however, a metal hydride serves as a proton acceptor, thus forming a hydrogen-hydrogen interaction. Neutron diffraction has shown that the molecular geometry of these complexes is similar to hydrogen bonds, in that the bond length is very adaptable to the metal complex/hydrogen donor system.
=== Circulatory system === Octopuses have a closed circulatory system, in which the blood remains inside blood vessels. They have three hearts; a systemic or main heart that circulates blood around the body and two branchial or gill hearts that pump it through the two gills. The systemic heart becomes inactive when the animal is swimming. Thus, the octopus loses energy quickly and mostly crawls. Octopus blood contains the copper-rich protein haemocyanin to transport oxygen. This makes the blood viscous and it requires great pressure to pump it around the body; blood pressures can surpass 75 mmHg (10 kPa). In cold conditions with low oxygen levels, haemocyanin transports oxygen more efficiently than haemoglobin. The haemocyanin is dissolved in the blood plasma instead of carried within blood cells and gives the blood a bluish colour. The systemic heart has muscular contractile walls and consists of a single ventricle and two atria, which attach it to each of the two gills. The blood vessels consist of arteries, capillaries and veins and are lined with a cellular endothelium unlike that of most other invertebrates. The blood circulates through the aorta and capillary system, to the venae cavae, after which the blood is pumped through the gills by the branchial hearts and back to the main heart. Much of the venous system is contractile, which helps circulate the blood.
=== Complications === Cats typically die due to complications associated with sepsis, dehydration, and disseminated intravascular coagulopathy (DIC). Leukocytopenia predisposes patients to secondary infections, especially bacterial and fungal, though secondary viral infections also occur. It has been stated that cats with FPLV may be at risk for endocarditis or cardiomyopathy (since CPV-2 is a well-known cause of viral myocarditis in young puppies), but a 2017 retrospective study concluded that "Feline Panleukopenia Virus Is Not Associated With Myocarditis or Endomyocardial Restrictive Cardiomyopathy in Cats".
Sources: en.wikipedia.org
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.
The lyophilized powder is usually stored at -20 °C or below. Dissolved solutions are less stable and should be prepared fresh when possible. Freeze-thaw cycling can reduce integrity.
It lacks aromatic residues, so it does not absorb strongly at 280 nm. Its negative charge and hydrophilic nature can affect chromatographic retention. These properties require method development for reliable separation.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.